Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-221-0 | CAS number: 3033-77-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on absorption rate:
Read-across strategy with (3-chloro-2-hydroxypropyl)trimethylammonium chloride.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - dermal (%):
- 0.685
Additional information
Basic toxicokinetics
Basic physico-chemical characteristics are available, which can be used to estimate toxicokinetic behaviour.
The molecular size of EPTAC is relatively small (MW 151.5 g/mol), which can be a facilitating factor in absorption through membranes. Dermal absorption
through passive diffusion could be expected to be low because the molecule is charged. Data from toxicological tests show that at least some absorption occurs via the gastro-intestinal (GI) tract and skin. Being a small molecule, it is possible that EPTAC pass through G-I tract membranes by passive penetration through aqueous pores at the tight junction. Findings from acute dermal toxicity data indicate that absorption occurs via the dermal route. More importantly, an in vitro skin penetration study is available for CHPTAC, a substance which has a closely related molecular structure. This allows also the assessment of the skin penetration properties of EPTAC. EPTAC can enter lungs as a residue in cationised starch dust. Theoretically, EPTAC could enter lungs also in water solution as aerosol particles. Depending on the particle size various parts of the respiratory system could be affected. The majority of big (> 10 μm) dust particles would probably stay in the nasopharyngeal mucous membranes. There, the residual EPTAC could dissolve in the mucus and be directly absorbed to blood circulation or it could be carried to the pharynx where it might enter the gastrointestinal tract. Smaller (<1 μm) particles could enter the tracheobronchial or alveolar space of the lungs where the substance could be released and enter the blood or be removed by the lymph circulation.
Distribution of EPTAC from vascular space to extracellular or intracellular compartment is probably slow due to the poor membrane passing quality. It may be possible for EPTAC to pass from the vascular space to the extracellular or intracellular compartment via aqueous pores. Entrance into fat is expected to be slow because of the low lipid/water partition coefficient [log Pow = -1.23].
Because EPTAC has a highly electrophilic epoxy group the metabolism is likely to occur mainly in the liver either via hydrolysis by an epoxide hydrolase or phase 2 enzymes, viz. different conjugation reactions such as glutathione S-transferases. These hydrophilic products are normally excreted effectively into urine.
Dermal abosrption
CHPTAC’s percutaneous absorption was examined in this study, which used a 2-14C radiolabelled CHPTAC and viable human and mouse skin membranes (TNO, 2003). The results of this study can serve as a worst case estimate for EPTAC as well. Because EPTAC is slightly more polar and is likely to bind to a higher extend to the stratum corneum due to its reactive epoxide function than CHPTAC, it is therefore likely that in human skin a lower amount is dermally absorbed to lower layers of the skin and systemically available.
Based on the findings in the in vitro skin penetration assay, a maximum penetration rate of 0.685 % was reached in the human skin. Since it is recommended by the TGD that the dose retained is the skin should also be taken in consideration 5 % would then be more appropriate (0.685+ (0.685 x 6.8)). However, this factor does not take into account the amount retained in the stratum corneum. Accounting for the amount retained in the stratum corneum the average absorbed ranged between 0.1-15 %. Taking the highest percentage retained in the stratum corneum would probably be too conservative, due to factors like exfoliation, washing and other processes in which the substance is lost to outside. Moreover, the epidermal uptake is likely to occur slowly because of high water solubility (>800 g/l) and a log P of less than zero. Therefore, an absorption percentage of 6 % will be taken for the risk characterisation.
Discussion on bioaccumulation potential result:
Basic physico-chemical characteristics are available, which can be used to estimate toxicokinetic behaviour. The molecular size of EPTAC is relatively small (MW 151.5 g/mol), which can be a facilitating factor in absorption through membranes. Dermal absorption
through passive diffusion could be expected to be low because the molecule is charged. Data from toxicological tests show that at least some absorption occurs via the gastro-intestinal (GI) tract and skin. Being a small molecule, it is possible that EPTAC pass through G-I tract membranes by passive penetration through aqueous pores at the tight junction. Findings from acute dermal toxicity data indicate that absorption occurs via the dermal route. More importantly, an in vitro skin penetration study is available for 3 -chlorohydroxypropyltrimethylammonium chloride (CAS 3327 -22 -8) (CHPTAC), a substance which has a closely related molecular structure. This allows also the assessment of the skin penetration properties of EPTAC. EPTAC can enter lungs as a residue in cationised starch dust. Theoretically, EPTAC could enter lungs also in water solution as aerosol particles. Depending on the particle size various parts of the respiratory system could be affected. The majority of big (> 10 μm) dust particles would probably stay in the nasopharyngeal mucous membranes. Therefore, the residual EPTAC could dissolve in the mucus and be directly absorbed to blood circulation or it could be carried to the pharynx where it might enter the gastrointestinal tract. Smaller (<1 μm) particles could enter the tracheobronchial or alveolar space of the lungs where the substance could be released and enter the blood or be removed by the lymph circulation.
Distribution of EPTAC from vascular space to extracellular or intracellular compartment is probably slow due to the poor membrane passing quality. It may be possible for EPTAC to pass from the vascular space to the extracellular or intracellular compartment via aqueous pores. Entrance into fat is expected to be slow because of the low lipid/water partition coefficient [log Pow = -1.23].
Because EPTAC has a highly electrophilic epoxy group the metabolism is likely to occur mainly in the liver either via hydrolysis by an epoxide hydrolase or phase 2 enzymes, viz. different conjugation reactions such as glutathione S-transferases. These hydrophilic products are normally excreted effectively into urine.
Discussion on absorption rate:
CHPTAC’s percutaneous absorption was examined in this study, which used a 2-14C radiolabelled CHPTAC and viable human and mouse skin membranes (TNO, 2003). The results of this study can serve as a worst case estimate for EPTAC as well. Because EPTAC is slightly more polar and is likely to bind to a higher extend to the stratum corneum due to its reactive epoxide function than CHPTAC, it is therefore likely that in human skin a lower amount is dermally absorbed to lower layers of the skin and systemically available.
Based on the findings in thein vitroskin penetration assay, a maximum penetration rate of 0.685 % was reached in the human skin. Since it is recommended by the TGD that the dose retained is the skin should also be taken in consideration 5 % would then be more appropriate (0.685+ (0.685 x 6.8)). However, this factor does not take into account the amount retained in the stratum corneum. Accounting for the amount retained in the stratum corneum the average absorbed ranged between 0.1-15 %. Taking the highest percentage retained in the stratum corneum would probably be too conservative, due to factors like exfoliation, washing and other processes in which the substance is lost to outside. Moreover, the epidermal uptake is likely to occur slowly because of high water solubility (>800 g/l) and a log P of less than zero. Therefore, an absorption percentage of 6 % will be taken for the risk characterisation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.